MaxCyte, Inc. (NASDAQ: MXCT) is a Healthcare company (Biotechnology) with a market capitalization of $121M. The Maz Rating grades it against the other companies in its sector.
MaxCyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.17, MaxCyte, Inc. trades at 3.5x sales and 0.8x book value. Over the last twelve months it generated about $34M of revenue and a net loss of $27M. It runs a gross margin of 78.0%, an operating margin of -87.7% and a net margin of -81.4%. It shows return on equity of -17.2%, return on invested capital of -17.9% and a free cash flow yield of -17.8%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 7.83. Over the past 52 weeks the share price ranged from $0.64 to $1.81, with a beta of 1.48.
MaxCyte, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.